NCT04102943View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients.

PHASE4UnknownINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

August 28, 2020

Study Completion Date

January 10, 2021

Conditions
Kidney Transplant
Interventions
DRUG

tacrolimus tablet

"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."

DRUG

tacrolimus capsules

"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY